In a symbolic display, activists invited conference participants to discard the injectable agents and commit to rapidly scaling up access to safer, more effective medicine.

Provocative distribution of yellow lemonade in urine collection cups calls attention to need for this simple, urine-based test.

Activists demand that Johnson & Johnson cut the price of bedaquiline in half, to no higher than $1 per day—$32 per person per month—double the price that researchers estimate bedaquiline could be sold for a profit.

Warns high prices of TB drugs restrict people's access to best drug-resistant TB treatment.

A new checklist from Treatment Action Group lays out simply the core elements of an adequate TB response.

The "Reality Check" dispels myths that have been circulated among members of the global TB community and used to justify pricing bedaquiline out of the reach of TB programs and patients.

First-ever targeted roadmap outlines steps to scale-up public-private health sector engagement to end TB.

Advocates ask Otsuka to lower the price of delamanid in line with Médecins sans Frontières target regimen cost of $500.

The guide highlights important safety and efficacy data reported thus far and offers advocacy recommendations for activists to take forward.

The Declaration falls short in its response to the leading infectious killer worldwide and the leading cause of death for people with HIV around the world.